Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial

Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019

(2020) Silke Gillessen et al.   EUROPEAN UROLOGY

Evaluating the Trade-offs Men with Localised Prostate Cancer Make Between the Risks and Benefits of Treatments: The COMPARE Study

(2020) Verity Watson et al.   JOURNAL OF UROLOGY

Investigating the impact of open label design on patient‐reported outcome results in prostate cancer randomized controlled trials

(2020) Guillaume Mouillet et al.   Cancer Medicine

Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol

(2018) M R Sydes et al.   ANNALS OF ONCOLOGY

Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer

(2018) Alicia K. Morgans et al.   JOURNAL OF CLINICAL ONCOLOGY

Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial

(2018) Kim N Chi et al.   LANCET ONCOLOGY

Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis

(2018) Susan Feyerabend et al.   EUROPEAN JOURNAL OF CANCER

OUP accepted manuscript

(2018)   JNCI-Journal of the National Cancer Institute

Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis

(2017) Larysa H.M. Rydzewska et al.   EUROPEAN JOURNAL OF CANCER

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

(2017) Karim Fizazi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

(2017) Nicholas D. James et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trustworthiness of Patient-Reported Outcomes in Unblinded Cancer Clinical Trials

(2017) Thomas M. Atkinson et al.   JAMA Oncology

Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer

(2016) Duncan C. Gilbert et al.   BJU INTERNATIONAL

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

(2016) Nicholas D James et al.   LANCET

Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data

(2016) Claire L Vale et al.   LANCET ONCOLOGY

Should multiple imputation be the method of choice for handling missing data in randomized trials?

(2016) Thomas R Sullivan et al.   STATISTICAL METHODS IN MEDICAL RESEARCH

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

(2015) Christopher J. Sweeney et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reporting of Patient-Reported Outcomes in Randomized Trials

(2013) Melanie Calvert et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30

(2012) K. Cocks et al.   EUROPEAN JOURNAL OF CANCER

Evidence-Based Guidelines for Determination of Sample Size and Interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30

(2010) Kim Cocks et al.   JOURNAL OF CLINICAL ONCOLOGY

STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer — A Multi-Arm Multi-Stage Randomised Controlled Trial

(2008) N.D. James et al.   CLINICAL ONCOLOGY

An international field study of the EORTC QLQ-PR25: A questionnaire for assessing the health-related quality of life of patients with prostate cancer

(2008) George van Andel et al.   EUROPEAN JOURNAL OF CANCER

A review of RCTs in four medical journals to assess the use of imputation to overcome missing data in quality of life outcomes

(2008) Shona Fielding et al.   Trials